Ab­b­Vie drops two ear­ly-stage AD­Cs, in­clud­ing Pfiz­er-part­nered on­col­o­gy pro­gram

Ab­b­Vie re­moved two ear­ly-stage an­ti­body-drug con­ju­gates from its pipeline, per a Wednes­day up­date to its pipeline web­page.

The Chica­go-area Big Phar­ma culled AB­BV-011 and the Pfiz­er-part­nered AB­BV-647. Ab­b­Vie and Pfiz­er did not im­me­di­ate­ly re­spond to in­quiries.

AD­Cs have made a splash in the on­col­o­gy R&D field in re­cent years, with As­traZeneca and Dai­ichi Sankyo’s En­her­tu chang­ing the land­scape for HER2 breast can­cer and Pfiz­er will­ing to dole out $43 bil­lion to buy Seagen and its pipeline of can­cer med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER